Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Med Case Rep ; 11(1): 141, 2017 May 19.
Artigo em Inglês | MEDLINE | ID: mdl-28521832

RESUMO

BACKGROUND: Short-term and long-term complications of transurethral prostate resection can be different in nature. Capsule perforation and subsequent fistulation after resection and electrovaporization is seldom reported in the literature. CASE PRESENTATION: Here we report the case of a 79-year-old caucasian man with capsule perforation after transurethral prostate resection and electrovaporization resulting in a severe and recurrent symphysitis and subsequent pelvic ring fracture. The bladder-symphysis fistulation was surgically removed and additional orthopedic surgery could be avoided after definitely solving the urological problem. CONCLUSIONS: Urologists should be aware of rare complications after transurethral resection and electrovaporization of the prostate.


Assuntos
Fraturas Ósseas/cirurgia , Osteíte , Dor Pélvica/diagnóstico , Sínfise Pubiana , Ressecção Transuretral da Próstata , Fístula da Bexiga Urinária/cirurgia , Idoso , Endoscopia por Cápsula/efeitos adversos , Seguimentos , Fraturas Ósseas/etiologia , Humanos , Masculino , Osteíte/diagnóstico , Osteíte/cirurgia , Dor Pélvica/etiologia , Dor Pélvica/cirurgia , Complicações Pós-Operatórias/cirurgia , Sínfise Pubiana/cirurgia , Recidiva , Ressecção Transuretral da Próstata/efeitos adversos , Resultado do Tratamento
2.
Circ Res ; 94(8): 1101-8, 2004 Apr 30.
Artigo em Inglês | MEDLINE | ID: mdl-15031263

RESUMO

Severe pulmonary hypertension is a disabling disease with high mortality. We investigated acute and chronic effects of iloprost, a long-acting prostacyclin analogue, and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in monocrotaline-induced pulmonary hypertension in rats. Twenty-eight and 42 days after administration of the alkaloid, right ventricular systolic pressure increased from 25.8+/-2.0 to 62.9+/-3.4 and 70.5+/-7.4 mm Hg, with concomitant decline in cardiac index, central venous oxygen saturation, and arterial oxygenation. Marked right heart hypertrophy was demonstrated by the strongly elevated ratio of right ventricle/left ventricle plus septum weight, and massive thickening of the precapillary artery smooth muscle layer was shown histologically. Western blot analysis demonstrated increased levels of matrix metalloproteinases (MMPs) -2 and -9 and increased gelatinolytic activities in isolated pulmonary arteries. In these animals, both intravenous iloprost and tolafentrine displayed characteristic features of pulmonary vasodilators. When chronically infused from days 14 to 28, both agents significantly attenuated all monocrotaline-induced hemodynamic and gas exchange abnormalities as well as right heart hypertrophy. Full normalization of all variables including right ventricle size was achieved on combined administration of both agents during this period. This was also true for MMP-2 and MMP-9 expression and activity. Moreover, when iloprost plus tolafentrine was used for late therapeutic intervention, with infusion from days 28 to 42 after full establishment of severe pulmonary hypertension and cor pulmonale, hemodynamic, gas exchange, and cardiac and pulmonary vascular remodeling changes were significantly reversed. We conclude that the combined administration of iloprost and a dual-selective phosphodiesterase 3/4 inhibitor prevents and reverses the development of pulmonary hypertension and cor pulmonale in response to monocrotaline in rats. This regimen may therefore offer a possible antiremodeling therapy in severe pulmonary hypertension.


Assuntos
Hipertensão Pulmonar/tratamento farmacológico , Hipertrofia Ventricular Direita/prevenção & controle , Iloprosta/uso terapêutico , Naftiridinas/uso terapêutico , Inibidores de Fosfodiesterase/uso terapêutico , Vasodilatadores/uso terapêutico , Remodelação Ventricular/efeitos dos fármacos , 3',5'-AMP Cíclico Fosfodiesterases/antagonistas & inibidores , Animais , Nucleotídeo Cíclico Fosfodiesterase do Tipo 3 , Nucleotídeo Cíclico Fosfodiesterase do Tipo 4 , Relação Dose-Resposta a Droga , Esquema de Medicação , Avaliação Pré-Clínica de Medicamentos , Quimioterapia Combinada , Gelatinases/análise , Hemodinâmica/efeitos dos fármacos , Hipertensão Pulmonar/induzido quimicamente , Hipertensão Pulmonar/complicações , Hipertensão Pulmonar/patologia , Hipertrofia , Hipertrofia Ventricular Direita/etiologia , Iloprosta/administração & dosagem , Iloprosta/farmacologia , Masculino , Metaloproteinase 2 da Matriz/análise , Metaloproteinase 9 da Matriz/análise , Monocrotalina/toxicidade , Músculo Liso Vascular/efeitos dos fármacos , Músculo Liso Vascular/patologia , Naftiridinas/administração & dosagem , Naftiridinas/farmacologia , Oxigênio/sangue , Inibidores de Fosfodiesterase/administração & dosagem , Inibidores de Fosfodiesterase/farmacologia , Artéria Pulmonar/enzimologia , Artéria Pulmonar/patologia , Troca Gasosa Pulmonar/efeitos dos fármacos , Doença Cardiopulmonar/etiologia , Doença Cardiopulmonar/prevenção & controle , Ratos , Ratos Sprague-Dawley , Vasodilatadores/administração & dosagem , Vasodilatadores/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA